Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065620 | 0.88 | CACNA1C (0.48) | KMT2AMEN1HTTMLKLALPL | |
| SCHEMBL14770508 | 0.87 | KMT2A (0.49) | KMT2AMEN1HTTALPLALPI | |
| SCHEMBL14770470 | 0.86 | MLKL (0.48) | KMT2AMEN1HTTMLKLALPL | |
| SCHEMBL12066561 | 0.86 | PRCP (0.43) | KMT2AMEN1HTTMLKLALPL | |
| SCHEMBL14770471 | 0.84 | MEN1 (0.55) | KMT2AMEN1HTTMLKLPOLB | |
| SCHEMBL12066005 | 0.83 | MEN1 (0.51) | KMT2AMEN1HTTMLKLPOLB | |
| SCHEMBL14770477 | 0.82 | MLKL (0.66) | KMT2AHTTMLKLALPLALPI | |
| SCHEMBL12065245 | 0.82 | ALPL (0.44) | KMT2AMLKLALPLALPIALPG | |
| SCHEMBL12066575 | 0.82 | MLKL (0.44) | KMT2AMEN1HTTMLKLALPL | |
| SCHEMBL12065616 | 0.80 | ALPL (0.42) | KMT2AMEN1HTTMLKLALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | KMT2A 4545/4885MEN1 2676/4885HTT 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.